GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (TSXV:APC.H) » Definitions » Cyclically Adjusted PB Ratio

Advanced Proteome Therapeutics (TSXV:APC.H) Cyclically Adjusted PB Ratio : 0.07 (As of May. 26, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Advanced Proteome Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Advanced Proteome Therapeutics's current share price is C$0.005. Advanced Proteome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2023 was C$0.07. Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio for today is 0.07.

The historical rank and industry rank for Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSXV:APC.H's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Advanced Proteome Therapeutics's adjusted book value per share data for the three months ended in Apr. 2023 was C$-0.001. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$0.07 for the trailing ten years ended in Apr. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Advanced Proteome Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Cyclically Adjusted PB Ratio Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.21 1.91 1.35 5.57 2.29

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.74 2.29 0.77 0.61 0.23

Competitive Comparison of Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio falls into.



Advanced Proteome Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.005/0.07
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2023 is calculated as:

For example, Advanced Proteome Therapeutics's adjusted Book Value per Share data for the three months ended in Apr. 2023 was:

Adj_Book=Book Value per Share/CPI of Apr. 2023 (Change)*Current CPI (Apr. 2023)
=-0.001/123.5712*123.5712
=-0.001

Current CPI (Apr. 2023) = 123.5712.

Advanced Proteome Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201307 0.003 97.261 0.004
201310 0.015 97.182 0.019
201401 -0.125 97.261 -0.159
201404 -0.032 98.920 -0.040
201407 0.058 99.315 0.072
201410 0.137 99.473 0.170
201501 0.132 98.209 0.166
201504 0.130 99.710 0.161
201507 0.188 100.579 0.231
201510 0.177 100.500 0.218
201601 0.173 100.184 0.213
201604 0.141 101.370 0.172
201607 0.128 101.844 0.155
201610 0.114 102.002 0.138
201701 0.110 102.318 0.133
201704 0.106 103.029 0.127
201707 0.069 103.029 0.083
201710 0.090 103.424 0.108
201801 0.029 104.056 0.034
201804 0.086 105.320 0.101
201807 0.045 106.110 0.052
201810 0.039 105.952 0.045
201901 0.050 105.557 0.059
201904 0.048 107.453 0.055
201907 0.042 108.243 0.048
201910 0.041 107.927 0.047
202001 0.035 108.085 0.040
202004 0.041 107.216 0.047
202007 0.014 108.401 0.016
202010 0.001 108.638 0.001
202101 0.010 109.192 0.011
202104 -0.036 110.851 -0.040
202107 -0.010 112.431 -0.011
202110 0.012 113.695 0.013
202201 0.038 114.801 0.041
202204 0.023 118.357 0.024
202207 0.035 120.964 0.036
202210 0.020 121.517 0.020
202301 0.012 121.596 0.012
202304 -0.001 123.571 -0.001

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Advanced Proteome Therapeutics  (TSXV:APC.H) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Advanced Proteome Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (TSXV:APC.H) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (TSXV:APC.H) Headlines

No Headlines